CPAA news you can use
About Us
Activities
Casefile
Info Centre
Resource
Directory
Contribute
Contact Us
Sitemap
Frequently Asked Questions
Articles
Reports
Useful Links
Book Review
Clipping File
Cancer Brochures  
Chat Transcripts  

 

Articles

Role Of Cancer Markers In Cancer Detection
My Fight Against Cancer
Colorectal Cancer Research from the PLCO Cancer Screening Trial

Ductal Carcinoma In Situ
How Breast Cancer Affects Fertility
The Breast Cancer Gene: What Should You Do?
Breast Cancer Survivors: Life After the Treatments End
Social Disparities in Tobacco Use in Mumbai, India
Ode-By Zahir
A Day Without Cancer-by Camille Gardo
Brain Tumours
Fighting Bladder Cancer
Fighting Colon Cancer
Caregivers Bible
Quitting Smoking
Alternative Therapies
Cancer Prevention and the Importance of Diet
Various types of Larynx Prostheses

 

 

Role Of Cancer Markers In Cancer Detection

Pathology Investigations are playing increasingly important role in detection and monitoring of various cancers such as Colonic cancer, Breast Cancer, Ovarian cancer, Liver cancer, Prostate cancer and Pancreatic cancer. These tests have to be performed only on clinician's advice and their interpretation is always done in conjunction with the overall clinical picture of the patient. They are simple noninvasive blood tests, which give extremely useful information about progression of cancer as well as early detection. Tumour Markers are used to monitor effect of therapy or recurrence of lesion, to follow the clinical course, or to pinpoint the tissue of origin. They are also useful to assess the extent of tumour and to estimate prognosis.

CEA:(Carcinoembryonlc Antigen)-For Intestinal Cancer

CEA is primarily used to monitor persistent, metastatic, or recurrent cancer of colon after surgery. CEA is the glycoprotein. CEA has significant value in monitoring of patients with diagnosed malignancies. Persistently elevated levels that are 5 to 10 times the upper limit strongly suggest presence of colon cancer. After successful therapy the levels decline. CEA should decrease to normal in 6-12 weeks after complete resection of colon. Declining CEA values have favorable prognosis. Determining prognosis in patients with colon carcinoma. Rising levels indicate recurrence of disease. CEA levels are .not recommended for screening procedure to detect cancer in general population.

CA 125: For Ovarian Cancer

CA 125 is a tumour marker for ovarian and endometrial carcinomas. It also increases in non-malignant conditions like endometriosis and pregnancy. It is a glycoprotein derived from coelomic epithelium; increased in benign or malignant conditions that stimulate peritoneal synthesis. It is used to monitor persistent or recurrent serous carcinoma of ovary in postoperative period or during chemotherapy. CA 125 level can decrease after the therapy and increase in relapse, residual disease and in metastasis. Interpretation of CA 125 result should be made taking into consideration the patient history and any other test result.

CA-19-9: For Pancreatic Cancer

CA 19.9 is the marker for both colorectal and pancreatic carcinoma. It is also increased in Hepatobiliary cancer. Very high concentrations predict surgically unresectable cancer. Elevated levels may indicate development of cholangiocarcinoma in patients with primary sclerosing cholangitis. Constant elevation of CA 19.9 reflects evolution of tumour and a poor response to therapy. A decrease in CA 19.9 assay value indicates positive response.

CA 15-3:For Breast Cancer

CA 15-3 is an aid in monitoring the disease status and disease progression of breast cancer. CA 15-3 should always be used in conjunction with other clinical methods for diagnosis and monitoring of breast conditions. It is a glycoprotein expressed on various adenocarcinomas, especially breast. It is also useful to detect breast tumour recurrence before symptoms appear and to monitor response to treatment. Elevated CA 15-3 values are also encountered in nonmalignant conditions like cirrhosis, hepatitis, benign diseases of ovary and breast. CA 15-3 values are not elevated in normal individuals.

AFP: For Liver Cancer and Germ cell Tumours of Testis and l Ovaries

AFP is oncofetal protein (glycoprotein), which is synthesized in fetal liver, yolk sac, which disappears in weeks following birth.    AFP elevation is typically found in individuals in several malignant conditions most notably in testicular carcinomas, primary hepatocellular carcinomas. It is a tumour marker for hepatoma, germ cell tumour of ovary and testis, teratoblastoma and yolk sac tumour. It is used for screening fetal defects during pregnancy. Changes in concentration can indicate effects of chemotherapy. In patients with clinical remission the AFP levels gradually decrease. AFP testing is not recommended as a screening procedure to detect cancer in general population.      

PSA:(Prostate specific antigen): For Prostate Cancer

Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland into seminal fluid: The PSA test measures the level of PSA in the blood. PSA is simple, safe and noninvasive test for early detection. It is normal for men to have low levels of PSA in their blood; however, prostate cancer or benign conditions can increase PSA levels. Clinical significance of PSA Levels: Increased levels of PSA may suggest the presence of prostate cancer. However, prostate cancer can also be present in the complete absence of an elevated PSA level, in which case the test result would be a false negative. PSA levels can be also elevated due to prostate infection, irritation, benign prostatic hypertrophy (enlargement) or hyperplasia (BPH) or recent ejaculation.

PSA also has a significant value in detecting metastatic or pre-existent disease in patients following surgical or medical treatment of prostate cancer. PSA test is widely accepted as an adjunct in the management of prostate cancer. A small amount of PSA is not protein bound and is called free PSA. Percentage of free PSA is lower in patients having prostate cancer than benign disease. In men with prostate cancer the ratio of free PSA to total PSA is decreased. The risk of cancer increases if the free to total ratio is less than 25%. The lower the ratio the greater the probability of prostate cancer. Measuring the ratio of free to total PSA appears to be particularly promising for eliminating unnecessary biopsies in men with PSA levels between 4 and 10 ng/mL.

By: Dr.Avinash A Phadke, Director of Wellspring Path labs, "Udyam", Ranade Rd, Shivaji Park, Dadar, Mumbal-28 Ph:24469250,24450283

 

[Top]

 

My Fight Against Cancer (The story of my father Pragji Dossa who had Cancer twice)- by Madhavsinh Dossa

CANCER DOES NOT MEAN CANCEL. Certainly not today when there are so many medically advances and discoveries, miraculous remedies to achieve victory over this dreadful disease and prolong the life of a person afflicted with it. 

I am writing this article about my respected father, late Shri PRAGJI DOSSA, (Born: 07-10-1907) an author, journalist, playwright, film writer, TV writer; radio plays writer, musician, singer and also sports-man, who suffered cancer twice: first in 1976-77, at the age of 70 and again at the old age of 83. Both times, he faced this disease bravely with undaunted spirit and courage. His larynx (voice box) was removed in 1977 following major surgery in Tata Memorial Hospital to remove a cancerous growth in his throat. In spite of this handicap, he continued to make his voice heard by millions all over the world through his   prolific pen. At the time of his laryngectomy operation in April 1977, he was a lecturer in I.N.T.’s   Children’s Wing and also in two other institutions. Being a singer himself, he had also studied Indian Classical Music as a pupil of Sangeet Samrat Pandit Omkarnathji Thakur. At that time he was writing a history of the Gujarati stage from the year 1852, besides writing stories, dialogues and screenplays of  feature films. On the third day after his operation, with the permission of his doctor, he started writing again. 

He also underwent plastic surgery twice on his neck as the skin had become dead due to the after effects of Cobalt Radiation. For this purpose, a piece of skin 6” x 2” in size was removed from his arm to be grafted on his neck as required. 

Two months later, he was awarded A.I.R. Akashwani Golden Jubilee Memento presented by then Prime Minister of India, Shri Morarji Desai. My father, Shri Pragjibhai was present at Akashwani Auditorium in New Delhi to receive this award. This was followed by five more awards and honours in the years 1978, 1979 and 1980; Gujarat Rajya Sangeet Nritya Natak Akedemy Award, Gold Medal and Tamrapatra presented by then Chief Minister of Gujarat, Shri Babubhai J. Patel in 1980 and his appointment as Special Executive Magistrate, Maharashtra State for 1980-1983. 

The death of my mother in July, 1982 was a severe blow which he had to accept as God’s will. 

My father continued with his writings from 3.45 in the morning, leading a disciplined life regularly practicing meditation and yoga. 

On his 75th birthday, in recognition of his great services and contributions in the field of Drama, Literature, Children’s Theatre, Films, Music and Radio,  he received messages of goodwill and felicitations from then Chief Minister of Gujarat, Shri Madhavsinh Solanki and also from France, Germany, London, Czechoslovakia and East Africa. He also received a letter from Washington, DC informing him that on this special occasion, a flag of the United States was flown over the capitol in his honour. This flag was subsequently sent to him with a certificate and picture of it flying over the capitol.   

This was immediately followed by the Soviet Land Nehru Award and Gold Medal presented to him by Shri Rajiv Gandhi in 1983. It is ironic that he had received this prestigious award earlier in 1966 from then Prime Minister, Smt. Indira Gandhi. He was given four more Awards and Honours from 1985 to 1989 by Chief Ministers of Maharashtra. 

 

Fate plays a prominent and unpredictable part in one’s life. In February 1990, during an investigation for enlargement of prostate, his biopsy revealed Adenocarcinoma. The cancer had struck him again. After a month, he was operated upon for the removal of the prostate. Though physically he was not strong and stout, mentally he was made of sterner stuff. Fate tested his strength very often but he was not to be cowed down. He possessed tremendous stamina and will power. In spite of having suffered cancer twice, a physically handicapped old and infirm person who had earlier lost his voice, fighting against all odds, trying to maintain himself, he continued to write and received five more awards and honours. 

He was appointed as one of the judges for Filmfare awards for best story in 1989 and for best screenplay in 1992, along with well known film maker, Shri B.R.Chopra. When he read my father’s bio-data, he was impressed by my father’s multi-faceted literary adventures and his achievements in so many fields. He wrote a wonderful letter to my father, which is treasured by our family today.

My father wrote 26 episodes of the T.V. serial “Savitri” in 1990-1991 for Smt. Hema Malini. He also wrote for T.V. serial “MAA (Adyashakti Bhuvaneshwari)” which was telecast on Zee T.V. in 1995. Many a times he had been interviewed on television when he spoke with the help of electronic larynx machine. As he had been interviewed for Akashwani for one-hour audio recording for Bombay Archives, so also even after his cancer operation, he was interviewed by the N.C.P.A. for one hour video recording for National Archives in March 1992. 

Only the patient knows how much a laryngeal cancer victim has to suffer even after a successful laryngectomy operation. On several occasions, my father had accumulation of phlegm in his wind-pipe and could not breathe properly. We had to rush him to Jaslok Hospital to alleviate the suffocation with the aid of suction machine. Dr. R.S.Rao who operated my father for Larynx Cancer in Tata Memorial Hospital in 1977 always took great personal care during his post-operative quarterly, half-yearly and later, yearly check-ups and also during emergencies. In spite of all these physical sufferings, he was active with new literary creations in various fields till his very last, whether it be Dramas, Plays, Radio Plays, Children’s Theatre & Plays for Children, Journalism, Novels, Films, T.V.Serials, Music, taking Interviews of Eminent Great Personalities or being interviewed by others. This, he always said, kept his mind and soul very active and energetic. 

In February 1996, his oesophagus (food-pipe) became constricted with the result that the food he ate was not able to pass through it. Even liquids like milk, tea and soups could only pass through drop by drop, resulting in it coming out by way of mouth or even nose. Ultimately in June 1996, he underwent endoscopic oesophageal dilatation operation. The food-pipe was widened a bit, since on account of his old age, the risk of fully widening it could not be undertaken. But within three months, the same problem started again, hence in October 1996 the same operation was performed. The surgeon informed my father that in case the trouble persisted, this operation could not be carried out again as there was a risk of the food-pipe rupturing. Thereafter, eating even half a chapati took him one to one and a half hours. His weight was reduced from 55 kg to 39 kg.   

In spite of this, his writings continued as usual much before sunrise. On 18th December, 1996, he was honoured with the prestigious Sangeet Natak Akademi Award for playwriting for 1995, presented to him by then President of India, Dr. Shankar Dayal Sharma at Rashtrapati Bhavan, in New Delhi. Even with his frail and weak body, at the very old age of 89 he showed great stamina and will power, travelling to New Delhi in cold and wintry weather to receive the award. It was a moving sight to see him slowly walking with the support of a stick in the Durbar Hall of Rashtrapati Bhavan. Thereafter, several associations paid tribute to  him on his receipt of this very prestigious award and honour.   

As fate would have it, on 15th August, 1997, while walking at home in the early morning, he lost his balance and fell down and fractured his right hip-bone. He was admitted to Bhatia General Hospital, where in spite of his pain, he insisted on carrying all his writing material. Through all the tests and intense pain he always mainatained a smiling face. He was operated on 19th August, but his heart gave way on the morning of 20th and he collapsed in the Intensive Care Unit. All efforts by the doctors and nurses to resuscitate and revive his heart were of no avail. 

At this time, he was working on “Bal-Pratibha”, on the lives of great men and women during their childhood. He had earlier written such stories for Mumbai Samachar. He told me that he wanted to write on this subject as he knew of many leaders whose childhood had been equally brilliant and noteworthy. 

Subsequently, V-Care Foundation gave him the “Victor Award” for deserving cancer patients who have faced the hardships and hazards of life after being afflicted with cancer bravely, posthumously on 14th February, 1998 for being “a source of inspiration and hope to cancer victims during a span of 20 years after suffering cancer through his immense courage, resilience and strength in his victory over cancer.” 

 

Pragji Dossa’s Creations after Suffering from Cancer:

138 Children’s Plays.

2.      78   Full Length Plays.

3.      14   Films - Story, Screenplay, Dialogues.

4.      140 Radio Programmes.

5.      130 T.V. Programmes.

6.      More than 1500 Articles in various Magazines and Newspapers.

7.      26 Books more published.

8.      Wrote Story, Screenplay, and/or Dialogues for Mythological Subjects - Maa Adyashakti Bhuvaneshwari, Durga, Savitri, Shiv Mahapuran, Narad etc. for Film and T.V. Producers.

9.      Interviews  of  several  eminent  famous  personalities  in  different  fields  taken and Published.

Operated on for larynx cancer on 01 – 04 – 1977:

Photographs in this article:

  • Pragji Dossa speaking with help of electronic larynx machine.

  • Pragji  Dossa receiving Soviet Land Nehru award and gold medal presented to him by Shri Rajiv  Gandhi,  at  Mavlankar Hall,  New Delhi  on  14 – 11 –1983.

  • Film actresses Hema Malini and Dina Pathak with producer Jayesh Gokani, set-designer Paresh Daru  and writer Pragji Dossa on the sets of his two children’s plays, “Choti Chatur” and “Dadano Dangoro” on  15 – 07 –1990.

  • Film actress  Asha  Parekh  with  Pragji  Dossa  on the sets of his children’s play “Tagad-Dhinna” on  02 – 07 – 1988.

  • Pragji  Dossa  receiving  Sangeet Natak Akademy award and tamrapatra  for playwriting  for the year 1995  presented to him by the President of India,  Dr. Shankar  Dayal  Sharma at Rashtrapati Bhavan, New Delhi  on  18 – 12 – 1996.

 

[Top]


Colorectal Cancer Research from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, or PLCO, is a large-scale clinical trial to determine whether certain cancer screening tests reduce death from cancer. In the PLCO Trial, researchers are testing flexible sigmoidoscopy. During a sigmoidoscopy, a thin, lighted viewing instrument is inserted into the rectum to examine the left, or distal, portion of the colorectum.
The detection rate of colorectal cancer in subjects undergoing screening in one study was 1.8 per 1,000 in women and 3.8 per 1,000 in men, while the detection rate for advanced adenomas (pre-cancerous polyps) was 23 per 1,000 in women and 43 per 1,000 in men.

The PLCO is testing the effectiveness of early prostate, lung, colorectal, and ovarian cancer detection using the following tests: digital rectal examination and blood prostate-specific antigen (PSA) testing for prostate cancer; chest X-ray for lung cancer; flexible sigmoidoscopy for colorectal cancer; and transvaginal ultrasound and the blood cancer antigen, CA-125, for ovarian cancer. Screening for cancer may enable doctors to discover and successfully treat the disease earlier, thus preventing deaths. Numerous epidemiologic and other studies are also part of this research.

Sponsored and run by the National Cancer Institute's (NCI) Division of Cancer Prevention, the PLCO trial is taking place at 10 screening centers across the United States: Birmingham, Ala.; Denver, Colo.; Washington, D.C.; Honolulu, Hawaii; Detroit, Mich.; Minneapolis, Minn.; St. Louis, Mo.; Pittsburgh, Pa.; Salt Lake City, Utah; and Marshfield, Wis. Between 1993, when the trial opened, and 2001, when enrollment completed, a total of 154,942 women and men between the ages of 55 and 74 joined PLCO. Screening of participants will continue until 2006. Additional follow-up will continue for at least 10 more years to determine the benefits or harms of the cancer screening exams being studied.

The PLCO trial also includes research on the genetic and environmental causes of cancer (prostate, lung, colorectal, ovarian and other types of cancer) and studies of new methods for the early detection of cancer, in collaboration with the NCI's Division of Cancer Epidemiology and Genetics. Together, prostate, lung, colorectal, and ovarian cancers account for 42 percent of all diagnosed cancers in the United States and nearly half of all cancer deaths (47 percent). An estimated 266,360 people will die of prostate, lung, colorectal and ovarian cancer in this country in 2005.

Colorectal cancer is the third most commonly diagnosed cancer among both men and women in the United States. Family history of the disease and a personal history of inflammatory bowel disease or polyps are factors known to increase a person's risk of colorectal cancer. A diet high in fat and low in dietary fiber also may increase a person's risk. The colon and rectum are the lowest portion of the digestive system. The colon is the last five or six feet of the intestine and the rectum is the last eight to ten inches of the colon. Because the areas are connected, cancer researchers often report this as a single type of cancer. In the PLCO trial, researchers are testing flexible sigmoidoscopy. During a sigmoidoscopy, a thin, lighted viewing instrument is inserted into the rectum to examine the left, or distal, portion of the colorectum. PLCO Subjects with a polyp or mass noted on sigmoidoscopy are often referred for further examination with colonoscopy, a procedure that examines the entire colorectum.

Patient Population, Trial Design, and Data Collection
The PLCO is a randomized, controlled trial in which 154,942 persons ages 55 to 74 at entry are randomly assigned to two study arms: half to undergo cancer screening (intervention group) and half to continue their normal health care routine (control group). Both groups answer yearly questionnaires about their health and give biologic samples (blood and tissue) for studies of cancer causes and of early markers for cancer (biomarkers). The sigmoidoscopy exam is offered twice--at the initial visit and at either the third or fifth annual visit, depending when the participant enrolled in PLCO. With the completion of enrollment and screening, researchers continue to follow participants in both groups for at least 13 years from the time they enrolled.

Results/Publications
The following PLCO analyses regarding colorectal cancer have been published, with the most recent studies listed first:

Screening and Related Clinical Studies
The PLCO trial offers a unique opportunity to examine the effectiveness of screening flexible sigmoidoscopy in a large, diverse population. Results from the initial screening and 12 months of follow-up were comparable to other studies.

Of 77,465 subjects randomized to the screening arm, 64,658 (83 percent) received the baseline flexible sigmoidoscopy exam. A total of 18 percent of women and 28 percent of men were found to have a positive screen (i.e., a lesion or mass reported). The detection rate of colorectal cancer in subjects undergoing screening was 1.8 per 1,000 in women and 3.8 per 1,000 in men, while the detection rate for advanced adenomas (pre-cancerous polyps) was 23 per 1,000 in women and 43 per 1,000 in men. Because of the large size of the study population, the broad geographic representation, and the follow-up criteria, the results of the PLCO trial will offer a benchmark for screening flexible sigmoidoscopy in the United States. Repeat screening flexible sigmoidoscopy three years after a negative exam will detect abnormalities or masses in the lower portion of the colon.

The PLCO trial is evaluating the effect of flexible sigmoidoscopy (FSG) on colorectal cancer mortality. The trial screened the intervention group upon entry to the study and then in three years. Individuals included in this analysis had an initial FSG that showed no abnormalities or masses and then underwent a screening FSG three years later. Of the 11,583 individuals without an abnormality or mass on initial FSG, 9,317 (80.4 percent) returned for repeat screening after three years. Of the people who returned, 1,292 (13.9 percetn) had a polyp or mass detected. Of those with a polyp or mass, 951 (73.6 percent) went on to have follow-up screening, colonoscopy or repeat FSG. In the distal colon, 292 (3.1 percent) were found to have an adenoma (a pre-cancerous polyp) and 78 (0.8 percent) were found to have either an advanced adenoma or cancer.

Data from the second screening for participants in the PLCO trial determined that excellent adherence to repeat screening with flexible sigmoidoscopy could be achieved. However, gender may impact adherence to repeat screening, with women less likely to return for follow-up screening. This study was comprised of 10,164 patients from the PLCO screening trial who had a negative/normal initial screen. These patients were scheduled for repeat flexible sigmoidoscopy three years after the initial screening. Almost 87 percent of eligible patients returned for repeat screening.

Measures of nonadherence with repeat sigmoidoscopy varied significantly according to gender. Compared with men, women missed the year-three clinic almost two times more often than men, and women who attended the year-three clinic refused repeat sigmoidoscopy more than two times more often than men.

Overall, patients' thoughts are similar and positive for both CT colonography (virtual colonoscopy) and traditional colonoscopy, with less favorable thoughts about bowel preparation. Most patients state that they would prefer virtual colonoscopy for future evaluation. A newer examination for detection of colorectal abnormalities is CT colonography, or "virtual colonoscopy." Computer-simulated three-dimensional images are used to examine the mucosal surface of the colon and a two-dimensional view is used to visualize the structure of the colon. This non-invasive alternative offers several advantages to the patient over colonoscopy: no need for sedation or monitoring of vital signs and no recovery period. Disadvantages are that the conventional bowel preparation program is still needed and that the insufflation (blowing gas into the colon to enlarge the area) is uncomfortable.

A total of 120 patients were recruited for this study. The patients who were included had an increased risk of colorectal abnormalities, due to; suspected polyps, rectal bleeding, blood in the stool, history of prior polyps, or a family or personal history of colorectal cancer. These patients received virtual colonoscopy followed by a traditional colonoscopy on the same day.
The study showed that for both virtual colonoscopy and traditional colonoscopy, patients' thoughts after the procedure were more favorable than what was expected. Patients expressed more favorable thoughts about colonoscopy for pain and embarrassment with most responses being "none" to "a little" for both exams. Overall appraisals of the tests were favorable and similar between colonoscopy and virtual colonoscopy. Patients mainly expressed "not unpleasant" to "a little unpleasant." Overall appraisal of the bowel preparation was the most negative.

Subjects who have undergone screening flexible sigmoidoscopy (FSG) and were found to have non-advanced adenomas (pre-cancerous polyps) in the lower portion of the colon have a similar risk for advanced abnormalities in the upper portion of the colon as subjects with no adenomas in the lower colon. Subjects with advanced adenomas in the lower colon, however, are at an increased risk. Patients found to have these abnormalities were referred for a colonoscopy to examine the upper portion of the colon.

Sigmoidoscopy is used to view the lower (distal) portion of the colon. When physicians find an abnormality in this area, studies have suggested that it is predictive of abnormalities in the upper (proximal) portion of the colon. Therefore, these patients are referred for a colonoscopy which is able to view the entire colon. A total of 8,802 patients underwent a full colonoscopy within one year of an abnormal baseline flexible sigmoidoscopy in PLCO, with two-thirds of those patients having a follow-up colonoscopy within three months. Subjects with advanced adenomas in the distal colon were found to be at increased risk for having advanced adenomas in the proximal colon; however, subjects with only non-advanced distal adenomas were not at increased risk for advanced proximal adenomas. Specifically, 12 percent of subjects with advanced distal adenomas, 4 percent of subjects with (only) non-advanced distal adenomas, and 4 percent of subjects with no distal adenomas were found to have advanced proximal adenomas.

In a group of patients who were found to have many polyps, radiologists were in agreement that virtual colonoscopy and traditional colonoscopy identified the same problems. The evaluation of computed virtual colonoscopy as a non-invasive examination of the colon continues to face new challenges. Early estimates of the diagnostic performance of virtual colonoscopy have been promising but variable.

The purpose of this study was to evaluate reader agreement by a radiologist for colorectal polyp detection in a group of patients who had many polyps. This group of patients, who were suspected of having polyps, was first examined with virtual colonoscopy and then traditional colonoscopy the same day. The images were analyzed independently by four experienced radiologists.
A total of 157 colorectal lesions ranging from 4 millimeters to 30 millimeters were found at colonoscopy and correlated with virtual colonoscopy findings. Overall analysis demonstrated a 75 percent agreement among the four readers.

Approximately 70 percent of individuals who undergo screening sigmoidoscopy are satisfied and find the procedure more comfortable than expected, and only 15 percent to 25 percent find the procedure unpleasant. Physicians should not project discomfort to patients as a reason for not requesting screening sigmoidoscopy. Physicians often cite patient discomfort as a reason for not requesting sigmoidoscopy, but patient experiences have not been well-studied. The researchers for this study adapted a survey which was designed to measure satisfaction with screening mammography. Questions about screening using flexible sigmoidoscopy centered on convenience, accessibility, staff interpersonal skills, physical surroundings, perceived technical competence, pain and discomfort, expectations and beliefs, and general satisfaction.

A total of 1,221 patients were surveyed after sigmoidoscopy. The results show that over 93 percent of the participants strongly agreed or agreed that they would be willing to undergo another examination, and 74.9 percent would strongly recommend the procedure to their friends. Regarding pain and discomfort, 76.2 percent strongly agreed or agreed that the examination did not cause a lot of pain, 78.1 percent stated that it did not cause a lot of discomfort, and 68.5 percent thought that it was more comfortable than expected. Fifteen percent to 25 percent of the patients indicated they had a lot of pain, great discomfort, or more discomfort than expected. Women were more likely to have significant pain or discomfort than men.

Among experienced abdominal radiologists using virtual colonoscopy, the ability to find polyps was similar with 2-D and 3-D (two dimensional and three dimensional) display techniques, although individual cases showed improved results with 3-D display techniques. Evaluation of reader agreement (independent radiologists detecting the same abnormalities) demonstrated good agreement for 3-D display, but not as good for 2-D display. Virtual colonoscopy is a rapidly growing and evolving technology for the detection of colorectal polyps and permits viewing with 2-D and 3-D display techniques. This method is being used as a potential noninvasive alternative for the detection of colorectal polyps.

Virtual colonoscopy was performed on 16 patients who were suspected of having polyps at a prior flexible sigmoidoscopy examination or barium enema examination. Three specific 2-D and 3-D display techniques were tested. Three experienced abdominal radiologists independently analyzed each test case and each patient was retested six weeks later. The results of readings 1 and 2 were similar for both 2-D and 3-D techniques among the readers. Overall observer agreement was good for the 3-D display techniques; however, observer agreement for 2-D techniques was lower.

Studies of Cancer Causes
Cigarette use is a risk factor for developing colorectal adenomas. Inherited variation in two genes (NQO1 and CYP1A1), which influence the activation of the cancer-causing substances in tobacco smoke, were found to increase risk for developing colorectal adenomas. In this study, researchers investigated the roles of variations in the CYP1A1 and NQ01 genes, combined with tobacco use, on the development of colorectal adenomas. These genes play a role in activating the cancer-causing substances in tobacco smoke. While tobacco use has been found to be a risk factor for developing colorectal adenomas, the role of these two genes is unclear. For this study, 772 people with at least one advanced adenoma and 777 people with no adenomas completed questionnaires about their lifestyles and had genetic tests done on their blood to determine if they had changes in these two genes.

The researchers found that the risk of having advanced colorectal adenomas was increased in smokers who had a variation in either the CYP1A1 gene or the NQO1 gene, and greatest in those with variations in both genes. In people who did not smoke, these gene variations did not affect their risk for developing colorectal adenomas.

Microsomal epoxide hydrolase (EPHX1) is responsible for breaking down carcinogens in cigarette smoke. Variations in this gene that increase EPHX1 protein activity appeared to increase risk for colorectal adenoma, particularly among recent and current smokers.It is is a protein that breaks down polycyclic aromatic hydrocarbons found in cigarette smoke, which are known to cause cancer. However, in the process of breaking down these carcinogens, EPHX1 creates another carcinogen, benzo(a)pyrene 7,8 dihydrodiol 9,10 epoxide (BPDE).

Researchers looked at two variations in the EPHX1 gene that are thought to affect the level of activity of the EPHX1 protein. They compared 772 people with advanced colorectal adenoma to 777 people without the disease. Detailed information on smoking history was collected from a risk factor questionnaire that participants filled out when they enrolled in the PLCO study. Non-smokers were considered those who did not smoke cigarettes for more than six months or who did not smoke pipes or cigars for more than one year. Current or recent smokers were those who quit less than 10 years before enrollment in the study.

Researchers found that those participants with variations in the EPHX1 gene, which led to higher protein activity, had an increased risk of colorectal adenoma. This was especially true among recent and current smokers.

Even though iron has been suggested as a risk factor for colorectal cancer, there was no relationship found between dietary intake of iron and risk of colorectal adenomas, the precursor condition to colorectal cancer. In addition, genetic variations that increase levels of iron in the blood were not found to be related to adenoma risk. Both iron intake and measures of iron in the blood have been suggested to be related to increases in the risk of colorectal cancer and adenoma. Researchers looked at iron intake and genetic variation in 679 people with advanced colorectal adenoma and 697 controls. Iron intake information was taken from participant responses to a food frequency questionnaire. Researchers found no relationship between iron intake and risk of adenoma.

Variations in the hemochromatosis gene (HFE) affects levels of iron in the blood. Researchers who looked at three different polymorphisms, or variations in this gene, did not find any relationship between the polymorphisms and risk of adenoma.

People who had a high calcium intake, greater than 1200 mg/d (milligrams per day), had reduced risk of colorectal adenoma, a pre-cursor condition to cancer.
Calcium can reduce the risk of colorectal tumors by reducing exposure to harmful compounds in the bowel, or by influencing various cellular activities in the colon, such as cell growth and death. This study compared supplemental and dietary calcium intake of 3,696 people with adenoma to 34,817 controls. Calcium intake information was derived from individual responses on a food frequency questionnaire. Researchers found that people with the highest intakes of calcium had the lowest risk of colorectal adenoma. The association between intake and risk was stronger for calcium from nondairy foods and supplements, and for adenoma of the distal colon, the part of the colon farthest from the stomach.

Variations in the calcium-sensing receptor gene were associated with advanced colorectal adenoma, a precursor condition to cancer. Also, a protective association was found between total calcium intake and advanced colorectal adenoma risk. The calcium-sensing receptor (CASR) is thought to mediate calcium's role in preventing cancer. Researchers looked at three common polymorphisms, or variations, in this gene in 772 people with advanced colorectal adenoma and 777 people without the disease. They found an association between advanced colorectal adenoma and these polymorphisms. This is the first study to evaluate variations in this gene in relation to risk of colorectal adenoma. Therefore, this study contributes new data that show a mediating role of CASR in preventing cancer.

This study also looked at calcium intake by reviewing participants' answers to a food frequency questionnaire which contained questions about dietary calcium intake and supplement use. A protective association was found for total calcium intake. For each additional 1,000 mg of calcium they took, participants had a 21 percent reduction in risk of advanced colorectal adenoma.

The VDR TaqI variation in the vitamin D receptor gene was not associated with risk of advanced colorectal adenoma, a pre-cursor condition to cancer. One vitamin D metabolite, 1,25(OH)2D, was not associated with advanced adenoma risk. Another vitamin D metabolite, 25(OH)D, was inversely associated with advanced adenoma risk in women but not in men. Vitamin D may be involved in the prevention of colorectal cancer, and this action may be mediated by the vitamin D receptor (VDR). Researchers analyzed a polymorphism, or variation in the VDR gene, called VDR TaqI, in 763 people with advanced colorectal adenoma and 774 people without the disease. They found no association between this polymorphism and adenoma.

Researchers also measured blood serum levels of two vitamin D metabolites, 1,25(OH)2D and 25(OH)D, in a subset of 394 cases and 397 controls. They found that serum levels of 1,25(OH)2D were not associated with adenoma risk. However, for the second metabolite, 25(OH)D, researchers found that higher levels were associated with a decreased adenoma risk in women, but not in men. In women, when comparing those in the highest quintile with those in the lowest quintile, the risk of advanced adenoma decreased by 73 percent.

People who had a high level of fiber in their diet were at lower risk of colorectal adenoma, a pre-cursor condition to cancer. The potential impact of dietary fiber on colorectal cancer risk is controversial. Researchers examined fiber intake from food and supplements in 3,591 people with adenoma, and 33,971 people without the disease. They found that risk of adenoma decreased with increasing intake of dietary fiber in both men and women. People in the highest quintile of fiber intake, who consumed approximately 24 more grams of fiber per day than those people in the lowest quintile, had a 27 percent decrease in adenoma risk compared with those in the lowest quintile.

[Top]

A Breast Cancer With a Built-In Quandary

Of all the debates surrounding the diagnosis and treatment of breast cancer in recent decades, the most persistent and perplexing one involves a very early cancer called D.C.I.S., or ductal carcinoma in situ. This cancer is noninvasive, confined to the milk duct where it arose. Some of these cancers will eventually become invasive, others never will. In autopsies, about 10 percent of women are found to have a ductal carcinoma that never became evident. Diagnoses of these early cancers have skyrocketed with the growth of screening mammography, breast X-rays done every year or two on presumably healthy women. This year, the American Cancer Society estimates, more than 50,000 women in the United States will be told they have the carcinoma.

About 80 percent of carcinomas in situ are found only on mammograms. They account for 20 to 30 percent of the breast cancers detected by mammography. A D.C.I.S. is usually too small to be felt in an examination by a woman or her doctor. When a mammogram reveals one of these carcinomas, it must be biopsied and the suspicious cells examined microscopically. Biopsy choices include fine-needle aspiration, which removes fluid and tiny bits of breast tissue; core-needle biopsy, which uses a larger needle to remove a cylinder of breast tissue; or surgical biopsy, in which the suspicious area is removed, including, perhaps, some surrounding normal looking tissue.

Then it is up to the pathologist to determine whether cancer is present, and if so, what type of D.C.I.S. it is. There are two main categories, a more aggressive type called comedo, which resembles a blackhead because it contains a core of dead cancer cells, and noncomedo. The comedo type may become an invasive cancer and, thus, less curable in three to five years; the noncomedo type may not progress to invasive cancer for a decade.

After the diagnosis comes the question, ''So what should I do?'' Should a woman have a mastectomy, a lumpectomy with or without radiation therapy, followed perhaps by a cancer-blocking drug like tamoxifen? Should she skip surgery and just take tamoxifen? Or should she do nothing, what doctors call ''watchful waiting,'' because the cancer may never become invasive before she dies of something else?

Until recently, the customary treatment was mastectomy, and there were good reasons for this approach. About 30 percent of women had more than one area of ductal carcinoma in situ in a breast, and in a significant percentage of cases treated with lesser surgery, the cancer recurred in the same breast. After a mastectomy, the recurrence rate is 1 to 2 percent.

Now, however, with improved therapies for early invasive breast cancer that do not involve removal of the entire breast, treatment choices are being debated. So how is a woman to decide? The quandary is similar to that faced by some men found through P.S.A. screening to have an early prostate cancer because it, too, may never become clinically significant. To arrive at a sensible and effective treatment decision, a woman should first know about the varying nature of the carcinomas and where her particular cancer fits along the spectrum from indolent to aggressive. She should take into account factors like her family history, her age and health status, her projected life expectancy and her ability to tolerate various treatment options. There is no emergency in deciding what to do after receiving a diagnosis of the ductal carcinoma. A woman has time to do research, ask questions of one or more physicians and discuss it with family members and with other women who have chosen various courses of treatment.

For example, Margaret in Minneapolis was 70 when a mammogram showed the cancer in one breast. After doing her homework, she decided that a simple mastectomy was her best chance for a lasting cure. She was not keen on undergoing radiation for five days a week over six weeks, which would have been necessary if she had chosen a lumpectomy. Her doctor thought there might be other suspicious areas in her breast that could become cancer if only the one known area was removed. Her husband said he would not find her any less attractive and lovable with one breast. And, given that her mother was still alive in her 90's, Margaret could expect to live decades longer and did not want to have to worry about a recurrence.

Debates abound as to whether some women with the ailment are being treated too aggressively and others not aggressively enough. In 1987, Nancy Reagan learned she had ductal carcinoma in situ. She chose a simple mastectomy. Some advocates for lesser surgery said she set back the movement to make removal of a breast a thing of the past for early cancers. Yet, she, like Margaret, may have had good reasons for her decision. It is not a matter for others to decide, especially when they do not have all the facts.

The final treatment decision depends largely on the the mammogram and the biopsy. A treatment guide from the cancer society states that ''in most cases, a woman can choose between breast-conserving therapy'' (lumpectomy, usually followed by radiation therapy) and simple mastectomy (removal of the entire breast). It is usually not necessary to remove lymph nodes, though the surgeon may choose to do a sentinel node biopsy, removing a few nodes to check for cancer spread.

The guide continues, ''Lumpectomy without radiation therapy is usually considered an option only for women with small areas of low-grade D.C.I.S.'' An eight-year study of 814 women found that radiation after lumpectomy significantly reduced the risk of recurrence. Radiation also greatly reduced the risk of a later invasive cancer.

The guide emphasizes that ''mastectomy may be necessary if the area of D.C.I.S. is very large, if the breast has several areas of D.C.I.S. or if lumpectomy cannot completely remove'' it. Mastectomy may also be the only choice for pregnant women, those with connective tissue disease and those who were previously irradiated in the breast area.

Another fact to consider is that not all carcinomas turn out to be noninvasive once removed. Dr. Monica Morrow of the Lynn Sage Breast Center at Northwestern University reports that 11 to 20 percent of the cases diagnosed with mammography will contain invasive cancer and warrant more definitive treatment, perhaps with a cancer-inhibiting drug taken for several years after surgery and radiation.

The good news is that few women with the ductal carcinoma die of breast cancer, even when it is conservatively treated. In the study that followed women for an average of eight years after lumpectomy with or without radiation, 1.6 percent (14 women out of 814) died of breast cancer. But recurrence rates vary, depending on the treatment, ranging from 1 to 2 percent at 10 years after a mastectomy to 32 percent at 12 years after a lumpectomy alone.

In a recent commentary in Cancer, experts at Rhode Island Hospital in Providence called the definitive treatment for the carcinoma an invasive-cancer preventive, similar to that used to treat polyps in the colon and precancer of the cervix.

[Top]

How Breast Cancer Affects Fertility

What there is to know about having a baby when you have breast cancer

More than 11,000 women under 40 are diagnosed with breast cancer in the U.S. each year. Breast cancer can be scary enough without wondering if it will also prevent you from having children. More and more American women are diagnosed with breast cancer in their childbearing years, and many want to know how the disease will affect their fertility. While there's no one-size-fits-all answer to this complex question, this article attempts to answer some tough questions including: What are the risks posed by cancer treatment, methods of preserving fertility, and ways cancer might affect future offspring.

How breast cancer treatment affects fertility depends largely on three factors: the type of treatment used, type and stage of the cancer at diagnosis, and the age of the patient.

Type of treatment

Not all breast cancer treatments affect fertility.

"If a patient needs only surgery and radiation and no chemotherapy, the treatment will have no impact on future fertility," Robert Barbierri, MD, chief of obstetrics and gynecology at Brigham and Women's Hospital in Boston, tells WebMD. The same, however, cannot be said for chemotherapy. Breast cancer patients treated with chemotherapy run the risk of developing premature ovarian failure or very early menopause. Almost four out of five women treated with cyclophosphamide -- an often-prescribed chemotherapy drug for treating breast cancer -- develop ovarian failure, according to Kutluk Oktay, MD, assistant professor of reproductive medicine and obstetrics and gynecology at Cornell's Center for Reproductive Medicine and Infertility. FertileHope, a nonprofit organization dedicated to disseminating education on infertility associated with breast cancer treatment, places the risk at 40% to 80%.

Type and Stage of Cancer

How advanced a cancer is upon detection, as well as what type it is, dictate whether chemotherapy will be required, thereby affecting the risk of side effects to the ovaries.

The more advanced the cancer upon detection, the greater likelihood that chemotherapy, which affects the whole body, will be used to treat it. For instance, invasive breast cancer typically requires systemic chemotherapy, whereas a small tumor with small nodes that is localized and contains a minimal threat of spreading may not. The type of tumor also impacts a patient's treatment options. Some breast cancers can be treated with the use of hormone-containing drugs. But a small percentage of breast cancer tumors are "hormonally insensitive," explains Susan Domcheck, MD, assistant professor of medicine at the University of Pennsylvania. What does this mean? "You can't use hormones to treat them. You're left with chemotherapy as your only option."

Age of Patient

Age plays a big role in patients' future fertility. "The age of the woman at the start of systemic chemotherapy is the biggest predictor of infertility," Barbierri tells WebMD. But why? "If you're 30, your fertility is already declining. Add to that chemotherapy, and you tack on a few more years. We know that chemotherapy induces menopause, particularly with women over 40," Domcheck says.

Preserving Fertility

Despite the fertility risks associated with breast cancer treatment (chemotherapy in particular), methods to preserve fertility prior to treatment offer hope to many patients.

To date, freezing embryos (fertilized eggs) created by in vitro fertilization (IVF) is the most widely used and effective method of preserving fertility. But there are potential downsides. IVF takes three to four weeks, a delay in cancer treatment that, depending on the stage and type of cancer, patients may or may not be able to afford. Sperm -- either from a partner or donor -- must be made available immediately to fertilize the eggs. And IVF is expensive -- anywhere from $10,000 to $14,000 per cycle.

Other methods of fertility preservation, albeit experimental, show promise. Egg freezing, which applies the same concept as embryo freezing, has proven less effective -- most likely because eggs are smaller, and less hardy, than embryos. There's also ovarian suppression during treatment, which "protects ovaries to some degree from chemical onslaught of chemotherapy," Barbierri tells WebMD. Freezing entire strips of ovarian tissue is a third technique under investigation; it involves surgically removing, storing, and later replacing the tissue in another part of the body.

Tamoxifen, a drug traditionally used to prevent breast cancer reoccurrence, was recently found to stimulate ovaries in breast cancer survivors during an IVF cycle, enhancing both egg and embryo production. This extra boost can combat infertility barriers such as age and the diminishing ovarian reserves, which occurs naturally with aging, notes Oktay.

Although males rarely develop breast cancer, it does happen. For male breast cancer patients who must undergo chemotherapy and want to preserve their fertility, freezing sperm is an effective option. "Since there are millions of sperm, even if you kill half in the freezing process, you still have a lot left," Barbierri explains.

Researchers' focus on fine-tuning methods of fertility preservation fuel optimism about its increasing viability. "A decade ago, there was practically no emphasis on fertility preservation. Today, there are several methods and thus a much greater potential," said Oktay.

Conception Concerns: Relapse, Harm to Offspring

For survivors who remain fertile, questions about conception remain. Relapse is one of them.

"A common clinical recommendation is that a survivor wait two years before attempting to become pregnant, since most serious relapses will occur within the first two years after treatment," said Barbierri. "If you wait two years, there's no strong evidence that pregnancy will influence the course of disease."

Survivors also worry that their offspring will be at risk for cancer. According to experts, that risk is small. "Only 5% of breast cancers are truly inherited via a specific genetic mutation. If you have an inherited genetic mutation, you have a 50-50 chance of passing it on to your children." To date, researchers have identified a few genetic mutations that contribute to breast cancer; these include BCRA-1 and BCRA-2.

What is the prognosis for offspring who do inherit one of these genetic mutations? "There does not appear to be an increased risk of childhood cancers. However, these children are at a slightly higher risk for developing ovarian and breast cancers," Domcheck says.

But genetics are only part of the picture.

"It's likely that an interplay between a collection of genes, when added to certain environmental factors, results in breast cancer," Domcheck says. Known environmental risk factors include moderate or heavy drinking (for women, two or more drinks per day), having children later in life, and obesity.

Survivors also question the impact of cancer treatment on future offspring. The news on this front is very encouraging. "There does not seem to be any increased risk of birth defects if the woman who's gone through breast cancer treatment gets pregnant. Even if the woman gets chemotherapy during pregnancy, fetuses do surprisingly well," said Domcheck.

Addressing Fertility With Your Doctor

Absorbing news of a breast cancer diagnosis as well as focusing on how it might affect future fertility can be overwhelming. But because oncologists are trained to provide the best cancer treatment available -- not necessarily in light of fertility options -- patients interested in seeking information on fertility need to be proactive. "A patient needs to say to herself, 'What do I want in the future' and ask the doctor, 'What's this [treatment] going to do with my future plans for fertility?'" says Ann Partridge, MD, MPH, breast oncologist and instructor at Harvard School of Medicine in Boston.

Others agree. "You need to have as much information as possible," says Karen Dow, PhD, RN, professor at University of Central Florida's School of Nursing. She suggests getting a third or even fourth opinion, ideally from doctors in different specialties -- oncology, reproductive endocrinology, gynecology -- since each will bring a unique perspective unique to the table.

"It would be wonderful if, in the future, doctors would all come together to say, 'Hey, here's what's out there, here's what it means to you,'" Dow says. But for now, it's up to the patient to seek information on her options, as early as possible.

[Top]

The Breast Cancer Gene: What Should You Do?

Is preventative mastectomy for women with breast cancer mutations a good idea?

Shortly after her mother died of ovarian cancer in 1999, Karen (who asked that her full name not be used) got a call from her first cousin, Joanne. Joanne, a cancer survivor, was in the process of researching their family's cancer history and had discovered that numerous female relatives had died from breast or ovarian cancer. She suggested that Karen consider getting tested for one of the inherited mutations -- called BRCA1 and BRCA2 --, which greatly increases the risk of breast cancer and can also increase the risk of ovarian cancer. If Karen had this genetic mutation, it would mean that she was also at high risk of developing breast cancer.

Karen, now 48, was tested at Memorial Sloan-Kettering Cancer Center in New York City and learned that in fact she did have a mutation on the BRCA1 gene, which means that her lifetime risk of ever developing breast cancer is as high as 80%. Depending on the age of a woman, the risk in the general female population is about 7%-8%. Because the lifetime risk of ovarian cancer is also high (15%-60%) in these women, this, too, was a concern. "Even with my family history, I was shocked to learn that I had the gene mutation, but at the same time I felt lucky because I was the first person in my family who had the chance to do something about it," says Karen. These inherited mutations are responsible for only about 5%-10% of breast cancers.

What to Do?

The question was, what exactly would she do?

Current recommendations for women with this inherited risk include:

  • Being closely monitored by monthly self-breast exams
  • Semiannual breast exams by a health care professional and annual screening mammograms
  • Having ovaries and/or having both breasts removed (these surgeries remove healthy organs to prevent cancer from developing)

While detection methods have come a long way, breast MRIs have been shown in studies to be better at detecting early-stage cancer in high-risk women. Screening tests, such as mammograms, when done regularly, can find cancers at an early stage and lower the risk of dying from breast cancer. But detection of a cancer is not the same as prevention of a cancer.

Bilateral prophylactic mastectomy is preventive surgery and is the only way to dramatically reduce the risk of developing breast cancer. Studies have shown that the procedure cuts the risk by nearly 90%.

In women with the BRCA mutation, preventive surgery to remove the ovaries (prophylactic oophorectomy) is most often done to reduce the risk of ovarian cancer, but it also cuts the risk of breast cancer. By removing the ovaries there are reduced amounts of hormones, such as estrogen, which stimulate breast cancer cells to grow.

Still, removing healthy organs is not a decision women should take lightly.

Instead, they should approach their options in a very practical and rational manner, says Mark E. Robson, MD, director of the Clinical Genetics Service at Memorial Sloan-Kettering. "They weigh the physical and psychological costs of having surgery against the cost of choosing screening and having it fail." A diagnosis of breast cancer is not the only thing women hope to escape; they also want to avoid potentially grueling cancer treatments.

Assuming they're done having children, women generally have an easier time accepting the idea of losing their ovaries than they do their breasts. "Unlike breasts, the ovaries are internal organs, so the psychological impact is less and there is less stigma involved," says Carolyn Kaelin, MD, MPH. Since menopause is inevitable anyway, many women can handle the prospect of it occurring a little sooner. Kaelin is a breast surgeon at the Dana-Farber Cancer Institute and director of The Comprehensive Breast Center at Brigham and Women's Hospital in Boston.

But oophorectomy only reduces the risk of breast cancer by 50%, which isn't all that meaningful if your risk was 80% to begin with -- making prophylactic bilateral mastectomy the surest route to real peace of mind (having both surgical procedures done cuts breast cancer risk by 95% or more).

Making the Surgery Decision

Robson says he's seen a wide variety of motivations among women who opt for this radical approach. Some have watched their mothers or other relatives die from breast cancer and will do anything to escape that experience. Others, particularly younger women, are primarily thinking of their children and wanting to be around for them. For women well past menopause, losing their breasts feels less traumatic than it might have at a younger age.

For Karen, it was a divorce and a new job that forced her hand. In January 2001, shortly after learning her genetic status, she had her ovaries removed, but wasn't able to face also losing her breasts at that time. She was living near Sloan-Kettering Cancer Center, going there every three months for screening, and felt in control of her situation. But when her husband asked for a divorce, it required her to find a new job; she ended up landing one in North Carolina, where getting top-notch cancer care would require a several-hour drive.

"I started seriously considering having the procedure at Sloan-Kettering before I left," said Karen. "I read all kinds of books and studies, talked to doctors and plastic surgeons and other women." In December, she will have both breasts removed, followed by breast reconstruction. "I feel very good about my decision," says Karen, noting that her friends and family have been supportive of her choice -- something that is not always the case.

"A lot of women who consider prophylactic mastectomy are doing so in a very measured, rational way and yet, at least in the U.S., they seem to be swimming upstream against people who are saying, 'What, are you crazy?'" explains Robson. "Those people don't understand the journeys, which have led these women to their decisions." What's most important, say Robson and Kaelin, is for a patient to be given all the information she needs to make a decision on her own, without any pressure from doctors. She should consult with a breast surgeon, a reconstructive surgeon, and most importantly, other women who have gone through it already. "One patient told me that the most helpful thing she was told was that it was perfectly reasonable to have the surgery and it was perfectly reasonable not to have it," recalls Robson. "It's just a personal choice and a woman should be supported no matter which way she goes."

Like Karen, the vast majority of women who choose prophylactic mastectomy opt for reconstructive surgery immediately afterward. During a bilateral mastectomy, a surgeon removes all breast tissue that is visible to the naked eye, including the nipple. The risk of cancer can never be 100% eliminated, says Kaelin, because there might be a wisp of a breast tissue cell that has dived down into the chest wall or beyond the normal boundaries.

Options for Breast Reconstruction

Options for breast reconstruction depend largely on a woman's individual physique. The most common procedure for women who've had both breasts removed involves saline or silicone breast implants. In alternative procedures, breasts are recreated using muscle and fat from other areas of the body. These tissues are used to create a sling-like structure on the chest wall; afterwards implants are placed in the position of the breast. With a TRAM flap (transverse rectus abdominal muscle), abdominal muscle and fat are used. A similar procedure, called a DIEP flap (deep inferior epigastric perforator), leaves the abdominal muscle in place and uses only fat and skin from that area. A different procedure uses back muscle.

Because two breasts must be recreated, a woman needs to have a large amount of appropriate tissue to spare for these procedures. Also, removing major muscles can cause weakness and pain in specific body regions. Nipple reconstruction usually involves a skin graft that's formed into a nipple shape and then tattooed to resemble a natural nipple in color. While reconstructed breasts have scars and no nipple sensation, Kaelin says that some women are genuinely "delighted" with their reconstruction.

But the real delight comes from the immense relief in no longer feeling like a ticking time bomb --something that Karen looks forward to. "My risk will be below that of the normal population; I won't need the surveillance anymore and getting health insurance won't be an issue," she says, pausing and then admitting that she is also pleased about a more superficial benefit of the surgery: "My new breasts will be perky for life!"

[Top]

Breast Cancer Survivors: Life After the Treatments End

The breast cancer treatments are over. Now what? Here's how to return to your "new normal."

The song says "It ain't over 'til it's over," but when you've had breast cancer, you discover that it's not even over when it's over. After a marathon of breast cancer diagnosis and treatment that may last six months to a year, you can hardly wait to get back to a normal life again. But the day of your last radiation treatment or chemotherapy infusion doesn't mark the end of your journey with breast cancer. Instead, you're about to embark on another leg of the trip. This one is all about adjusting to life as a breast cancer survivor. In many ways, it will be a lot like the life you had before, but in other ways, it will be very different. Call it your "new normal."

From your relationships with your family and your spouse to eating habits and exercise, breast cancer will change your life in ways that last well after treatment ends. How do you fight lingering fatigue? What should you eat to help prevent a breast cancer recurrence? Will you ever have a regular sex life again? These are just a few of the questions that may nag at you as you make the transition from breast cancer treatment to breast cancer survival.

"Chemobrain" and Other After-Effects

You watched the last dose of chemotherapy drip from the IV into your veins six months ago. Your hair has really started to grow back. Maybe it's curly where it once was straight, or a lot grayer than before, but it's hair. You have eyebrows again. So why are you still so tired? When are you going to feel like you again? "Your body has just been through an enormous assault, and recovery is a huge thing. You're not going to just bounce back right away," says oncologist Marisa Weiss, MD, founder of Breastcancer.org and the author of Living Beyond Breast Cancer. "You've been hit while you're down so many times: with surgery and anesthesia, perhaps with multiple cycles of chemotherapy, perhaps with radiation."

Two of the biggest hurdles women with breast cancer face post-treatment are fatigue resulting from chemotherapy and/or the accumulated effects of other treatments, and a phenomenon some women have dubbed "chemobrain" -- mental changes such as memory deficits and the inability to focus. If you tried, you probably couldn't pick two more frustrating and troubling side effects for women handling busy lives, managing careers, and caring for families. "You expect them to go away as soon as treatment ends, and they don't," says Mary McCabe, RN, director of the Cancer Survivorship program at Memorial Sloan-Kettering Cancer Center in New York.

That such a program as McCabe's exists is a testament to the changing nature of what it means to have cancer. Women with breast cancer, like other people with a cancer diagnosis, are now surviving for so much longer, and in such large numbers, that some hospitals are opening entire departments devoted to survivorship. The National Cancer Institute has also launched a special research area dedicated to studying what it means to survive cancer.

How long after breast cancer treatment ends can you expect fatigue, "chemobrain," and other post-treatment side effects to persist? Everyone's different, of course, but as a general rule of thumb, Weiss tells her patients to expect a recovery period about the same time from your first "cancer scare" moment to the date of your last treatment. So if you found a lump or had a suspicious mammogram in April, and had your last radiation treatment in December, it may be August or September of the following year before you reach your "new normal."

"Even then, that doesn't mean that you're fully back to yourself again, but by then you should have a sense of where you're going to be, what your energy level will be, and so on," says Weiss. Ongoing treatments, like tamoxifen or other hormonal therapies such as arimidex, aromasin or femara, or reconstructive surgery, can affect the process. "I have a lot of patients who are in their second year of dealing with this. Yes, their main anti-cancer treatment may be over, but they're still figuring out how to manage the side effects of hormonal therapies and so on. It can feel like an endless process."

Breast cancer survivorship, Weiss observes, is a marathon, not a sprint. That means learning to handle the symptoms that stick around after treatment ends, says Sloan-Kettering's McCabe, by using those adaptive strategies you learned while on chemotherapy or recovering from surgery. "You need to continue to have planned periods of rest, and think about what times in the day and after what activities you tend to find yourself most tired," she says. "If chemobrain is still bothering you, continue using tricks like writing things down, posting reminders to yourself, and asking people to repeat information." Some women find it helps to keep a daily diary, noting down the times when fatigue or mental fogginess hit hardest, to help them plan around it.

A Chance to Make Some Life Choices

Make sure your family and your officemates understand that just because treatment is over, that doesn't mean that you're going to be able to jump right back into running the carpool, coaching soccer, and traveling to conferences a week out of every month. "Everyone's ready for treatment to be over, not just you, and although they've been supportive, your friends and family may be expecting you to spring back right away," says McCabe. "It's an education process. They need to understand that when the therapy stops, that doesn't mean that the effects of the therapy stop immediately." Manage your expectations, urges Weiss. "Decrease the stress and the pressure on you in whatever ways you can. There are a lot of decisions you can make to take charge of how your life goes while you're in this recovery process."

For example, you may have certain ideas about how your house should look, how much income you're going to have, and what your commitments to your community need to be. Decide which of those things are really important to you and which ones don't matter quite as much. Let the less-important ones slide or find someone else to do them.

Gina Shaw is a medical writer who was treated for breast cancer in 2004, and now calls herself a "joyful breast cancer survivor."

[Top]

Social Disparities in Tobacco Use in Mumbai, India: The Roles of Occupation, Education, and Gender-(Glorian Sorensen, Prakash C. Gupta and Mangesh S. Pednekar, 09/07/2005)

Objectives. We assessed social disparities in the prevalence of overall tobacco use, smoking, and smokeless tobacco use in Mumbai, India, by examining occupation-, education-, and gender-specific patterns.

Methods. Data were derived from a cross-sectional survey conducted between 1992 and 1994 as the baseline for the Mumbai Cohort Study (n=81 837).

Results. Odds ratios (ORs) for overall tobacco use according to education level (after adjustment for age and occupation) showed a strong gradient; risks were higher among illiterate participants (male OR=7.38, female OR=20.95) than among college educated participants. After age and education had been controlled, odds of tobacco use were also significant according to occupation; unskilled male workers (OR=1.66), male service workers (OR=1.32), and unemployed individuals (male OR=1.84, female OR=1.95) were more at risk than professionals. The steepest education- and occupation- specific gradients were observed among male bidi smokers and female smokeless tobacco users.

Conclusions. The results of this study indicate that education and occupation have important simultaneous and independent relationships with tobacco use that require attention from policymakers and researchers alike. (Am J Public Health. 2005;95:1003-1008. doi:10.2105/AJPH.2004.045039)

Tobacco use in low-income and middle-income countries is predicted to contribute to an increasing share of the global burden of disease in future decades.1 Eighty-two percent of the world's 1.1 billion smokers now reside in low- and middle-income countries, where, in contrast to declining consumption in high-income countries, tobacco consumption is on the rise.1 Indeed, the World Health Organization's Framework Convention on Tobacco Control underscores the importance of tobacco control efforts within developing countries as part of a worldwide strategy to reduce the health, economic, and social consequences of tobacco use.2 Addressing this growing public health problem requires attention to increasing social disparities in patterns of tobacco use. Across high-, middle-, and low-income countries, smoking rates are highest among individuals of low socioeconomic position.3

Indicators of socioeconomic position vary across studies; often education, occupation, and income level are used interchangeably to measure socioeconomic position.4 It is important, however, to examine multiple indicators of socioeconomic position simultaneously if one is to understand their combined impact and thereby provide more complete descriptions of social inequalities in tobacco use. In particular, insufficient attention has been focused on occupational disparities in tobacco use, given the role of occupation in linking education and income as well as its role as a determinant of health in its own right, through hazardous workplace exposures. Indeed, recent analyses of US data indicate that education does not represent a "stand-in" surrogate for occupation, or vice versa; rather, they reflect distinct social constructs making overlapping as well as independent contributions to patterns of tobacco use.5

In this study, we examined social disparities in tobacco use in India, where multiple forms of tobacco consumption complicate attempts to reduce its overall impact on public health. It has been estimated that 65% of men use some form of tobacco, including 35% who smoke, 22% who use smokeless tobacco, and 8% who engage in both forms of tobacco use.6,7 About one third of women use at least one form of tobacco, although rates among women vary considerably by region (from approximately 15% to approximately 65%).6,7 In general, cigarettes account for an estimated 20% of tobacco consumption; about 50% of tobacco is consumed in the form of bidis, that is, traditional, leaf-wrapped unfiltered cigarettes.8,9

In previous studies, different patterns have been observed in the educational gradient in tobacco use depending on the type of tobacco used. Whereas overall tobacco use has been shown to be highest among those with the least education, cigarette smoking rates have been shown to increase with increasing education.10 In India, because of their low cost, bidis are more commonly smoked than cigarettes by individuals of lower socioeconomic position; in turn, cigarettes are more commonly consumed among those with greater financial resources.10,11 (Bidi smoking has been shown to pose significant health hazards.12-14) A similar socioeconomic gradient has been observed for the use of smokeless tobacco, including chewing tobacco, snuff, burnt tobacco, powder, and paste.7,15

In general, men in India smoke as well as chew or apply tobacco, whereas women generally chew or apply tobacco, with the exception of the few areas where prevalence rates of smoking among women are high.7,16 It is estimated that more than 150 million men and 44 million women in India use tobacco in various forms,14 and approximately 635000 deaths in India are attributed to tobacco each year. Tobacco-related cancers constitute about half of the total cancer incidence among men and about 20% among women.8

The purpose of this study was to assess educational and occupational differences in the prevalence of tobacco use, including total tobacco use, bidi and cigarette smoking, and smokeless tobacco use, in a large sample of residents of Mumbai, India. In addition, we sought to assess the joint effects of occupation and education level on tobacco use after controlling for other key determinants of use (i.e., gender and age).

METHODS

Baseline data for the Mumbai Cohort Study were collected between 1992 and 1994 in Mumbai (Bombay), India.17 The overall purpose of this prospective cohort study was to assess mortality associated with tobacco use in Mumbai.

Study Population

Mumbai is a large, densely populated city whose population was approximately 12 million people in 2001.18 The city is divided into 3 sectors: the main city, the suburbs, and the extended suburbs. This study exclusively focused on the main city. The sampling frame comprised the city's electoral rolls, which are updated via house- to-house visits before each major election. From these rolls, assumed to be relatively complete given that almost all adult residents are entitled to vote, data were derived on the name, age, gender, and address of all individuals older than 18 years. The electoral rolls were organized by geographical areas; sampling was based on the smallest unit, the "polling station," which included 1000 to 1500 eligible voters. Selection of polling stations excluded those involving a large proportion of apartment complexes with high levels of security; results of the pilot data collection indicated the need for this exclusion owing to the difficulty of gaining access to such buildings.

At the selected polling stations, all individuals 35 years or older who were listed on the electoral rolls were eligible to be interviewed. The age cutoff of 35 years was selected as a result of the study's overall goal of studying tobacco-attributed mortality. In selected geographical areas, lists were supplemented to include individuals who were not listed on the electoral rolls but whose residence status was confirmed by a "ration card." These cards, issued by the Bombay Municipal Corporation, serve as a proxy for residence cards and permit access to all city and state governmental services; individuals identified in this manner represented approximately 5% of the overall sample.

Of the individuals approached and invited to participate in the study, the nonresponse rate was less than 1%. It was not possible to contact approximately 50% of the individuals included on the lists as a result of incomplete addresses, houses being demolished, changes of residence, and inaccessibility of residences (often owing to security considerations). A total of 99 598 adults (40 071 men and 59 527 women) were recruited and surveyed. In the analyses presented here, we excluded respondents who reported that they were retired (n=15 223) or had missing data for occupation (n=2538). The final sample comprised 81 837 respondents.

Data Collection

The survey was conducted by trained interviewers within participants' households. Hand-held computers were used to record data at the time of the interview. Interviews were conducted in the local languages, including Hindi and Marathi. No surrogate responses were permitted.

Measures

The primary outcome in the present analyses was tobacco use, categorized as follows: (1) having no habit in either the past or present ("never user"), (2) former user (including smoking and use of smokeless tobacco), (3) current smokeless tobacco user (including betel quid, mishri, and creamy snuff), (4) current cigarette smoker, and (5) current bidi smoker (including other forms of smoked tobacco as well, e.g., chilum and hooka). Smokers who also used smokeless tobacco were classified as smokers in these analyses.

Occupation was assessed according to respondents' self-reports. Following the standard Indian classification system, occupations were coded as follows: skilled workers, unskilled workers, traders, service workers, and professionals.19 Additional categories \included unemployed and housewife. Women were considered as housewives unless they were currently employed or looking for employment. Retirees were excluded from the analyses. Education level was classified as illiterate, primary school (up to 5 years of education), middle school (6-8 years of education), secondary school (9-12 years of education), and college (including both some college and attainment of college degree). Gender and age data were also collected.

Data Analysis

Descriptive statistics were calculated for the overall population as well as for men and women separately. Logistic regression was used in conducting multivariate analyses. The response variable, tobacco use, was converted into a dichotomous variable in which current tobacco users (including users of any form of tobacco) were compared with current nonusers. Multivariate analyses of cigarette and bidi smoking were conducted only among men because of the extremely low prevalence (less than 0.5%) of smoking among women. SPSS statistical software (SPSS Inc, Chicago, Ill) was used in analyzing the data.

RESULTS

Sample Characteristics

Men represented about one third of the sample (Table 1). More than 40% of men were employed in service positions, and one third were unskilled workers, whereas a large majority (88%) of women were classified as housewives. Women were generally less educated than men; 45% of women were illiterate, as compared with 11% of men. In addition, only 5% of women had completed secondary school or college, whereas 16% of men had done so. Overall, about a quarter of the participants were between the ages of 35 and 39 years; more than a third were between 40 and 49 years of age.

Tobacco Use Prevalence: Bivariate Analyses

Patterns of tobacco use differed dramatically according to gender (Table 1). While women were less likely than men to have ever used tobacco (26% vs 41%), they were more likely to currently use smokeless tobacco (57% vs 44%). Smoking prevalence rates were 27% among men and, as mentioned, less than 0.5% among women (thus, data on female smokers are not shown separately in Table 1 or described in subsequent analyses). Among male smokers, 12% were cigarette smokers and 15% were bidi smokers. Overall, 2% of the sample members were former tobacco users, an indicator of cessation rates.

TABLE 1-Tobacco Use, by Gender, Occupation, Education, and Age: Mumbai Cohort Study

Among men as well as women, professionals were least likely to have ever used tobacco, whereas unskilled workers and unemployed individuals were most likely to have done so. Use of smokeless tobacco was more common than smoking across all occupational categories. Rates of smokeless tobacco use among women were highest among unskilled workers, those who were unemployed, and housewives. Among men, smokeless tobacco use was especially prevalent among service and unskilled workers and unemployed individuals. Bidi smoking among men followed a similar pattern, with high prevalence rates among unemployed individuals and unskilled workers. In contrast, cigarette smoking was most common among professionals and traders. Self-reported rates of former tobacco use ranged from less than 2% to 6%.

There was a strong gradient in tobacco use according to education level. Among both men and women, the rate of smokeless tobacco was highest among the illiterate and lowest among those with a college education. Among men, the prevalence of bidi smoking was highest among those at low levels of education, but the prevalence of cigarette smoking was highest among those at the highest education levels.

Multivariate Analyses

Table 2 presents gender-specific tobacco use odds ratios comparing current tobacco users, current cigarette smokers, current bidi smokers, and current smokeless tobacco users with individuals reporting no current use of any type of tobacco. Odds ratios according to occupation and education were adjusted for age and the other relevant model variable (i.e., either occupation or education). The reference category for occupation was professional, and the reference category for education was college.

Tobacco use was inversely related to education level across all types of tobacco use. The magnitudes of the odds ratios were especially large among those with no more than a primary school education; in addition, in this subgroup, odds ratios were particularly pronounced among women who used smokeless tobacco and men who were bidi smokers. Relative to participants in the reference educational category (college), odds ratios for all forms of tobacco use were significantly higher among those in the other educational categories. After adjusting for age and education, we also observed an inverse relationship between cigarette smoking and education (see Table 2).

TABLE 2-Adjusted Odds Ratios (and 95% Confidence Intervals) for Various Forms of Tobacco Use (vs No Current Habit), by Education, Occupation, and Gender: Mumbai Cohort Study

Although the magnitudes of the relationships were not as large, occupation continued to play an important role in patterns of tobacco use when education and age were controlled. In the case of men, odds ratios for smokeless tobacco use remained statistically significant among unskilled workers, service workers, and unemployed individuals, and the odds ratios for bidi smoking remained significant among unemployed individuals and both skilled and unskilled workers. None of the odds ratios for cigarette smoking were significant. After education level had been controlled, male traders were actually less likely to use smokeless tobacco than were professionals, suggesting an interesting interaction between education and occupation. Among women, after control for education level and age, only the odds ratios for those who were unemployed remained statistically significant.

DISCUSSION

The present results demonstrate the important roles of education and occupation in tobacco use patterns in India. Research in the West has consistently documented a strong socioeconomic gradient in tobacco use, with higher rates of use among those of greater social disadvantage.4,5,20-22 Indeed, Jarvis and Wardle23 concluded that, in Western countries, "any marker of disadvantage that can be envisaged and measured, whether personal, material or cultural, is likely to have an independent association with cigarette smoking." Recent evidence documents the same socioeconomic tobacco use gradient in India; tobacco use has been found to be higher among individuals at lower levels of education,10,11,15,24-27 of lower castes,15,27 and with lower standards of living.27,28 (Other research, however, has failed to reveal an association between tobacco use and socioeconomic position.29)

Education is a powerful correlate of tobacco use patterns.10 In this study, after adjustment for occupation and age, all forms of tobacco use followed an inverse linear pattern in terms of educational level; similar results have been reported by others.11,15,27 Odds ratios were alarmingly high among individuals with no more than a primary school education, particularly, as described earlier, women using smokeless tobacco and men smoking bidis. Of note, when we adjusted only for age (data not shown), the direction of the relationship between education and cigarette smoking among men was reversed relative to the bivariate relationships presented in Table 1. Unlike the use of other forms of tobacco, cigarette smoking was most prevalent among the younger groups within this sample; among male participants, age contributed significantly to both education- and occupationspecific odds of cigarette smoking. These findings underscore the importance of adjusting for age in analyses such as those described here.

Our analyses also offer evidence of the independent effects of occupation and education on tobacco use among men; even after control for education, odds ratios for occupation were statistically significant among the most disadvantaged workers in regard to bidi smoking and use of smokeless tobacco. One interesting exception in these occupationspecific results involved the odds of using smokeless tobacco among male traders; although the overall prevalence of smokeless tobacco use was somewhat higher among traders than among professionals, a lower proportion of traders than professionals in each of the various educational groups used smokeless tobacco (data not shown).

Occupation appeared to carry more weight in regard to men's tobacco use than that of women. Because a large proportion of the women in this sample were housewives and 45% were illiterate, it is not surprising that education was a more important indicator of socioeconomic position than current occupation. The "housewife" category provided insufficient information to adequately describe socioeconomic position because it included women living in a range of social and economic circumstances. In addition, education appeared to swamp any influence of occupation among women; for example, the odds of smokeless tobacco use were more than 20 times greater among women who were illiterate than among women with a college education.

Unemployment was a particularly powerful predictor of tobacco use. In the case of all comparisons, even those taking education into account, unemployed individuals were at the highest risk of using tobacco, a relationship that has been reported in other populations as well.30-34 In addition, unemployment was most strongly associated with bidi use among men (OR=3.5). Unemployment is an indicator of increased economic disadvantage and associated stressors such as poor housing conditions, unmet needs for food, and potential lack of social connectedness.23,35 Expenditures on tobacco products have been found to represent a significant portion of the daily incomes of Indian residents in low income categories, including unemployed individuals.36

The present findings demonstrate the need, instudies assessing social disparities in tobacco use, to examine occupation and education separately as well as simultaneously. This will allow researchers to gain a more complete understanding of such disparities than might be the case when considering either indicator alone.5 Others have noted the importance of considering multiple indicators of socioeconomic position in understanding patterns of tobacco use.5,23,37 Education and occupation are likely to operate through differing pathways. Education is one of the most widely used indicators of socioeconomic position, given that it is easy to measure, applicable to individuals both inside and outside the labor force, and stable across the life course. It has consistently been shown to be a strong correlate of tobacco use, both in India and elsewhere.5,10,11,15,22,24-26 Nonetheless, it may fail to capture some of the elements of socioeconomic position expressed by occupation; occupation may further indicate one's standing in the community, reveal aspects of the normative environment prevalent within one's occupational "culture," and serve as a marker for the general conditions present at one's workplace.5,37

Several caveats must be noted in interpreting our results. For example, our education and occupation data were based on self- reports. In addition, the complexities of obtaining, recording, and coding occupational data can lead to misclassification.37-40 Furthermore, our occupational categories were combined into broad groupings, which could have contributed to biased estimates in terms of the gradients observed. Nonetheless, these groupings provided greater precision than those used in earlier tobacco use research in India; in these studies, occupation was grouped into even more general categories.41 We collected data at the individual level, not the household level, and thus our data on socioeconomic position may have been incomplete, particularly in the case of women.37 Future studies could include other indicators of socioeconomic position, such as caste or different standard of living measures.

In addition, as described earlier, the present data were collected as part of the initial data collection effort in a prospective cohort study; they were not part of a surveillance study designed to assess population prevalence rates of tobacco use. The sample was not a random or representative sample of the population. In particular, we excluded individuals who resided in upper-middle- class and upper-class housing complexes that were not accessible as a result of security issues. Thus, the proportions of individuals in different occupational categories might not have been comparable to the proportions in other cities or in India as a whole. Nonetheless, our findings provide important insight into the interrelationships between education, occupation, and tobacco use. Moreover, although the proportions of different occupation types and the prevalence rates of tobacco use may not have been representative of the general population, it is highly unlikely that the interrelationships observed would have been seriously affected by our sampling methods.

Identifying occupation- and educationspecific disparities in tobacco use can provide a useful "signpost" indicating inequities that need to be addressed by policymakers and the broader community through allocation of resources.42 Our results indicate that tobacco use in India follows a social gradient mirroring that reported for Western countries. If one is to shed light on patterns of disparities, it is important to consider multiple indicators of socioeconomic position, including both education and occupation, as well as gender. Additional research elucidating the differing pathways by which occupation and education may influence tobacco use can inform future policies and other interventions.

References

1. Gajalakshmi CK, Jha P, Ranson K, Nguyen S. Global patterns of smoking and smoking-attributable mortality. In: Jha P, Chaloupka FJ, eds. Tobacco Control in Developing Countries. New York, NY: Oxford University Press Inc; 2000:11-39.

2. Framework Convention on Tobacco Control Geneva, Switzerland: World Health Organization; 2003.

3. Jha P, Chaloupka FJ. Curbing the Epidemic: Governments and the Economics of Tobacco Control. Washington, DC: World Bank; 1999.

4. Bobak M, Jha P, Nguyen S, Jarvis M. Poverty and smoking, In: Jha P, Chaloupka FJ, eds. Tobacco Control in Developing Countries. New York, NY: Oxford University Press Inc; 2000:41-61.

5. Barbeau E, Krieger N, Soobader M. Working class matters: socioeconomic disadvantage, race/ethnicity, gender, and smoking in the National Health Interview Survey, 2000. Am J Public Health. In press.

6. Tobacco or Health: A Global Status Report. Country Profiles by Region. Geneva, Switzerland: World Health Organization; 1997.

7. Gupta PC. A Database on Tobacco in the SouthEastAsia Region. New Delhi, India: World Health Organization; 2003.

8. Sharma DC. India's welcome to foreign tobacco giants prompts criticism. Lancet. 1998;352:1204.

9. Mudur G. India finalises tobacco control legislation. BMJ. 2001;322:386.

10. Gupta PC. Socio-demographic characteristics of tobacco use among 99,598 individuals in Bombay, India, using hand-held computers. Tob Control. 1996;5: 114-120.

11. Narayan KM, Chadha SL, Hanson RL, et al. Prevalence and patterns of smoking in Delhi: cross sectional study. BMJ. 1996;312:1576-1579.

12. Dikshit RP, Kanhere S. Tobacco habits and risk of lung, oropharyngeal and oral cavity cancer: a population-based case- control study in Bhopal, India. Int J Epidemiol 2000;29:609-614.

13. Wasnik KS, Ughade SN, Zodpey SP, Ingole DL. Tobacco consumption practices and risk of oro-pharyngeal cancer: a case- control study in Central India. Southeast Asian] Trop Med Public Health. 1998;29:827-834.

14. Pais P, Fay MP, Yusuf S. Increased risk of acute myocardial infarction with beedi and cigarette smoking in Indians: final report on tobacco risks from a case-control study. Indian Heart J. 2001;53:731-735.

15. Rani M, Bonu S, Jha P, Nguyen SN, Jamjoum L. Tobacco use in India: prevalence and predictors of smoking and chewing in a national cross sectional household survey. Tob Control. 2003;12:E4.

16. Sudarshan R, Mishra N. Gender and tobacco consumption in India. Asian J Womens Stud. 1999;5:83-114.

17. Gupta P, Mehta HC. Cohort study of all-cause mortality among tobacco users in Mumbai, India. Bull World Health Organ. 2000;78:877- 883.

18. Census of India 2001: Series 28. Maharashtra: Provisional Population Totals. Maharashtra, India: Dept. of Census Operations; 2001.

19. National Classification of Occupations, NCO Divisions. New Delhi, India: Directorate General of Employment and Training, Ministry of Labour; 2004.

20. Giovino G, Pederson L, Trosclair A. The prevalence of selected cigarette smoking behaviors by occupation in the United States. In: Work, Smoking and Health: A NIOSH Scientific Workshop. Washington, DC: Centers for Disease Control and Prevention; 2000: 22- 31.

21. Graham H. Promoting health against inequality: using research to identify targets for intervention. A case study of women and smoking. Health Educ J. 1998;57:292-302.

22. Cigarette smoking among adults: United States, 2001. MMWR Morb Mortal Wkly Rep. 2001;52:40.

23. Jarvis MJ, Wardle J. Social patterning of individual health behaviours: the case of cigarette smoking. In Marmot M, Wilkinson RG, eds. Social Determinants of Health. Oxford, England: Oxford University Press Inc; 1999:240-255.

24. Gupta P. Why we should care: at-risk populations. Paper presented at: Oslo Cancer Congress, June-July 2002, Oslo, Norway.

25. Sen U. Tobacco use in Kolkata. Lifeline. 2002;8:7-9.

26. Gajalakshmi CK, Peto R. Studies on tobacco in Chennai, India. Paper presented at: 10th World Conference on Tobacco and Health, August 1997, Beijing, China.

27. Subramanian SV, Nandy S, Kelly M, Gordon D, Smith GD. Patterns and distribution of tobacco consumption in India: cross sectional multilevel evidence from the 1998-1999 National Family Health Survey. BMJ. 2004;328:801-806.

28. National Family Health Survey (NFHS-2), 1998-1999: India. New Delhi, India: World Health Organization, Regional Office for South- East Asia; 2002.